Lehrman Biopharma consulting has accomplished the
following:
following:
Past successes / Current partners
 |
| |
 |
| |
 |
| |
 |
 | Enhanced the bioavailability and increased in vivo half-life by | |
| modifying protein structure and small molecule salt form. | ||
| Screened and selected formulations for proteins and small | |
| molecule drug candidates. Several of these modified candidates and formulations are currently in clinical trials. | ||
| Developed robust analytical methods for final product | |
| characterization and stability testing. In some cases, these methods have been transferred to contract laboratories. | ||
| Selected and managed contract organizations that have | |
| manufactured cGMP compliant drug substance and drug product. | ||
| Authored documents in support of regulatory filings. | |
Of special interest:
Protein aggregation is a critical concern to companies that
are developing biotechnology-derived drugs. Russ has
significant experience and expertize in this area. Check his
recent article on this topic:
Protein aggregation is a critical concern to companies that
are developing biotechnology-derived drugs. Russ has
significant experience and expertize in this area. Check his
recent article on this topic: